The global anthrax treatment market was valued at around US$ 520.2 Million at the end of 2021. The market is projected to register a 7.4% CAGR and top a valuation of US$ 1,146.0 Million by 2032.
The development of novel therapeutics for the anthrax treatment population, increased funding for research, and rising anthrax infection rates are the key drivers driving the market growth for anthrax treatments.
Anthrax is a dangerous disease that can affect both humans and animals like sheep, horses, goat, and cattle. It is a potentially fatal infection brought on by the Bacillus anthracis bacteria.
Gram-positive Bacillus anthracis is a rod-shaped bacterium that is typically spread by animals. Anthrax spreads primarily by three routes: the digestive route, the airborne route, and skin-to-skin contact. Anthrax has become very well-known in recent years as a result of its use in bioterrorism.
Anthrax spores have been employed in biological warfare and for mass infection. The most typical form of anthrax infection is a dermal infection, which is not contagious. It develops eschar an ulcer with a black centre.
Anthrax consumption can result in diseases that are extremely lethal. The deadliest variety is anthrax that is inhaled. With a high fever, rapid breathing, shortness of breath, blood vomiting, sweating, and chest symptoms that escalate to heart attacks, anthrax acquired through inhalation advances quickly.
Pneumonia and severe respiratory collapse are common signs of anthrax in humans with respiratory illness. The most common methods for diagnosing anthrax infection include a CT scan, an X-ray of the lungs, a blood test for anthrax antigens, and a biopsy skin test. For the diagnosis of anthrax, kits based on chemiluminescence and enzyme-linked immunosorbent assay (ELISA) are available.
Anthrax is a Category A agent with significant bioterrorism potential, according to the CDC. Only BioThrax, produced by Emergent BioSolutions, Inc., is FDA-approved for use as pre-exposure defense against anthrax infections.
| Attributes | Details |
|---|---|
| Anthrax Treatment Market Value in 2021 | US$ 520.2 Million |
| Anthrax Treatment Market Value in 2032 | US$ 1,146.0 Million |
| Anthrax Treatment Market CAGR (2022 to 2032) | 7.4% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global anthrax treatment market is anticipated to expand as a result of the increased need for more effective anthrax treatment methods. Additionally, the rising healthcare investments in emerging regions, rising patient awareness of available treatments, and rising research funding is supposed to influence the anthrax treatment market's growth.
Some additional aspects anticipated to further fuel generating revenue in the anthrax treatment market include growing public-private partnerships to facilitate fresh technologies for the inventive and successful treatment of anthrax.
North America has dominated the global market as a result of substantial government financing, encouraging policies, and the presence of significant players in the region. The research of novel medicines for the treatment of anthrax is supported by organizations like the CDC, which is one of the factors driving market expansion in the Americas.
Moreover, Asia Pacific is supposed to grow at the highest CAGR during the forecast timeline due to the awareness management programs that enhance potential strategies to improve the quality of care with a cost effective approach.
Additionally, Europe is supposed to show steep increase in the anthrax treatment market due to increased domination of clinically integrated treatments for anthrax and growing implementation of unique device implementation (UDI).
Principal Consultant
Alembic Pharmaceuticals, Integrated Bio Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Bayer AG, Pfizer Inc., EMERGENT, Sanofi, Elusys Therapeutics, Porton Biopharma, Lupin, Soligenix, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., ARISTO Pharmaceuticals Private Limited, INDOCO REMEDIES LTD., Paratek Pharmaceuticals, Inc., DEINOVE, BlueWillow Biologics., GC Biopharma, corp., and Altimmune
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 7.4% 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Million, Volume in Units, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segment Covered | Anthrax Type, Drug-Class, Distribution Channel |
| Region Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Argentina, Germany, United Kingdom, France, Spain, Italy, Russia, China, Japan, South Korea, India, Malaysia, Indonesia, Thailand, Australia, New Zealand, GCC Countries, South Africa, North Africa, Turkey |
| Key Players | Alembic Pharmaceuticals; Integrated Bio Therapeutics Inc.; Sun Pharmaceutical Industries Ltd.; Zydus Group; Bayer AG; Pfizer Inc.; EMERGENT; Sanofi; Elusys Therapeutics; Porton Biopharma; Lupin; Soligenix; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.; ARISTO Pharmaceuticals Private Limited; INDOCO REMEDIES LTD.; Paratek Pharmaceuticals, Inc.; DEINOVE; BlueWillow Biologics.; GC Biopharma, corp.; Altimmune |
| Customization | Available Upon Request |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global anthrax treatment market is anticipated to register a CAGR of 7.4% during the forecast period.
Alembic Pharmaceuticals, Integrated Bio Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Bayer AG, Pfizer Inc., EMERGENT, Sanofi, Elusys Therapeutics, Porton Biopharma, Lupin, Soligenix, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., ARISTO Pharmaceuticals Private Limited, INDOCO REMEDIES LTD., Paratek Pharmaceuticals, Inc., DEINOVE, BlueWillow Biologics., GC Biopharma, corp., and Altimmune, among others are some prominent anthrax treatment market
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Market Analysis and Forecast 6.1. Anthrax Type 6.2. Drug Class 6.3. Distribution Channel 7. Global Market Analysis and Forecast, By Anthrax Type 7.1. Cutaneous Anthrax 7.2. Inhalation Anthrax 7.3. Gastrointestinal Anthrax 7.4. Injection Anthrax 8. Global Market Analysis and Forecast, By Drug Class 8.1. Fluoroquinolone 8.2. Tetracycline 8.3. Others 9. Global Market Analysis and Forecast, By Distribution Channel 9.1. Hospitals Pharmacies 9.2. Retail Pharmacies 9.3. E-commerce 9.4. Drug Stores 9.5. Others 10. Global Market Analysis and Forecast, By Region 10.1. North America 10.2. Latin America 10.3. Europe 10.4. East Asia 10.5. South Asia 10.6. Oceania 10.7. The Middle East and Africa (MEA) 11. North America Sales Analysis and Forecast, by Key Segments and Countries 12. Latin America Sales Analysis and Forecast, by Key Segments and Countries 13. Europe Sales Analysis and Forecast, by Key Segments and Countries 14. East Asia Sales Analysis and Forecast, by Key Segments and Countries 15. South Asia Sales Analysis and Forecast, by Key Segments and Countries 16. Oceania Sales Analysis and Forecast, by Key Segments and Countries 17. The Middle East and Africa (MEA) Sales Analysis and Forecast, by Key Segments and Countries 18. Sales Forecast by Anthrax Type, Drug Class, and Distribution Channel for 30 Countries 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 20. Company Profile 20.1. Alembic Pharmaceuticals 20.2. Integrated Bio Therapeutics Inc. 20.3. Sun Pharmaceutical Industries Ltd. 20.4. Zydus Group; Bayer AG 20.5. Pfizer Inc. 20.6. EMERGENT 20.7. Sanofi 20.8. Elusys Therapeutics 20.9. Porton Biopharma 20.10. Lupin; Soligenix 20.11. Takeda Pharmaceutical Company Limited 20.12. Teva Pharmaceutical Industries Ltd. 20.13. ARISTO Pharmaceuticals Private Limited 20.14. INDOCO REMEDIES LTD. 20.15. Paratek Pharmaceuticals, Inc. 20.16. DEINOVE 20.17. BlueWillow Biologics 20.18. GC Biopharma, corp. 20.19. Altimmune
Explore Healthcare Insights
View Reports
Anthrax Treatment Market
